Gilead Sciences Korea's Sofosbuvir/Velpatasvir-based chronic hepatitis C drugs Epclusa and Vosevi are expected to be listed on the 1st of next month at insurance drug prices of 117,000 won and 128,800 won, respectively. The government and insurance authorities expect to reduce health insurance finances as prices are agreed to be cheaper than alternative drugs during drug price negotiations. According to industries on the 20th, the Ministry of Health and Welfare is planning and proceeding with the "Amendment to the Pharmaceutical Benefits List and Salary Limit Table" on the 1st of next month based on the results of the NHIS' drug price negotiations with Gilead Science Korea.